Tevogen Bio

680 posts

Tevogen Bio banner
Tevogen Bio

Tevogen Bio

@TevogenBio

Specialty immunotherapy biotech developing off-the-shelf precision #Tcell therapeutics in #oncology, #neurology, and #virology. $TVGN

New Jersey Katılım Mart 2021
222 Takip Edilen621 Takipçiler
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 tevogen.com/press_release/… 🔹Loss from operations declined 51%, from $53.6 million in 2024 to $26.1 million in 2025. 🔹Q1 2026 showed continued improvement, with loss from operations decreasing to $5.4 million, a 48% improvement year-over-year. 🔹The Company is evaluating potential revenue-generating acquisitions that may support positive cash flow and business diversification. 🔹The Company continues to prioritize disciplined capital allocation and avoiding unnecessary dilution. More in the link. Thank you for your continued trust and support. $TVGN #ShareholderValue #CapitalDiscipline
Tevogen Bio tweet media
English
0
5
6
311
Tevogen Bio
Tevogen Bio@TevogenBio·
#ICYMI: Tevogen’s January 30, 2026 announcement regarding the Board’s evaluation of a potential one-time special cash dividend to shareholders. Full press release: globenewswire.com/news-release/2… $TVGN #ShareholderValue #CapitalDiscipline @DrRyanSaadi
Tevogen@Tevogen

📰 globenewswire.com/news-release/2… Tevogen announced its Board will evaluate a potential one-time special cash dividend, contingent on future revenue and earnings milestones and Board approval. $TVGN @Nasdaq #ShareholderValue #CapitalDiscipline

English
0
1
3
336
Tevogen Bio
Tevogen Bio@TevogenBio·
Tevogen congratulates our founder and CEO, @DrRyanSaadi, on being named to the 2026 #Innovate100 list as part of @JamesBarrood Innovation+ initiative. A recognition celebrating leaders helping shape the future of innovation across New Jersey. Innovation courses through every aspect of Tevogen. From our unique business model to precision T cell therapeutics at Tevogen Bio and artificial intelligence-driven drug discovery through @TevogenAI, we remain committed to advancing healthcare to be more accessible, efficient, and impactful. We are honored to be part of @NJGov vibrant innovation ecosystem and congratulate the many visionary leaders recognized on this year’s Innovate100 list. $TVGN #Innovate100 #Innovation #HealthcareInnovation #ArtificialIntelligence #NewJerseyInnovation #Leadership
Tevogen Bio tweet media
English
0
1
8
161
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 tevogen.com/press_release/… “Having The Patel Family, LLP continue to support Tevogen reflects a shared belief in both our mission and our long-term vision for building a more accessible and sustainable healthcare model,” said Tevogen founding CEO @DrRyanSaadi. “We believe this financing along with an existing ATM offering and loan agreement, provides the company with access to adequate capital to reach revenue milestones. $TVGN #PIPE #RevenueGrowth #HealthcareInnovation
Tevogen Bio tweet media
English
0
3
5
272
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… “Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said @Head_TevogenAI Mittul Mehta, “As we begin exploring commercial pathways, our focus remains on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.” $TVGN #PredicTcell #ArtificialIntelligence #MachineLearning #DrugDiscovery #Immunotherapy
Tevogen Bio tweet media
English
0
4
6
297
Tevogen Bio
Tevogen Bio@TevogenBio·
🔗 njbiz.com/2026-njbiz-hea… 👏Congratulations to our Founder and CEO, @DrRyanSaadi , on being named to the 2026 @NJBIZ Health Care Power List.👏 This recognition comes as Tevogen continues its evolution into a diversified, revenue-generating healthcare enterprise, focused on building a healthcare model that prioritizes both innovation and accessibility. Congratulations, Ryan, and to all those shaping the future of healthcare. $TVGN #Healthcare #HealthcareInnovation #Leadership
English
1
1
4
321
Tevogen Bio
Tevogen Bio@TevogenBio·
🔗 databricks.com/blog/tevogen-b… As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure to process and analyze hundreds of millions of peptide sequences across diverse disease areas. This recent feature by @databricks highlights elements of that journey, how modern data architecture can support complex biological modeling and help move from static datasets toward adaptive, continuously learning systems. Thank you, Databricks, for supporting @TevogenAI’s journey toward what we consider the “holy grail”: 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘵𝘩𝘦 𝘱𝘳𝘰𝘵𝘦𝘰𝘮𝘦 𝘧𝘰𝘳 𝘢𝘯𝘺 𝘨𝘪𝘷𝘦𝘯 𝘤𝘰𝘮𝘣𝘪𝘯𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘱𝘳𝘰𝘵𝘦𝘪𝘯 𝘢𝘯𝘥 𝘏𝘓𝘈 𝘵𝘺𝘱𝘦. $TVGN #ArtificialIntelligence #MachineLearning #Bioinformatics #DataEngineering #AIinHealthcare
Tevogen Bio tweet media
English
0
4
9
475
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… “I am pleased with the rapid progress towards a cash flow positive healthcare enterprise,” said Tevogen CEO @DrRyanSaadi. "With the advanced-stage evaluation of this CRO, alongside additional acquisition opportunities under review, there may be potential to generating closer to $100 million in annual revenue, I hope to update further in the near term. These are not just financial metrics; they are the economic fundamentals required to support our core mission of delivering affordable, next-generation healthcare solutions in oncology, rare disease, and beyond, while maintaining the company’s fiscal sovereignty.” $TVGN #CRO #RevenueGrowth #HealthcareInnovation #GlobalHealth
Tevogen Bio tweet media
English
0
2
5
577
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… With compliance restored, Tevogen continues to advance its evolution into a diversified, fully integrated healthcare enterprise, combining immunotherapy, artificial intelligence, and disciplined capital allocation to drive long-term value. The Company’s strategic direction includes evaluating targeted acquisition opportunities that complement its core platforms. These initiatives are part of a broader effort to transition toward a cash-flow-positive operating model while maintaining a strong commitment to affordability and efficiency. $TVGN #Nasdaq
Tevogen Bio tweet media
English
0
1
4
292
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… From Risk to Reward: Modernizing the Data Estate to Power Enterprise AI Wednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade. Agentic Data Engineering on Microsoft Fabric: Building Adaptive Pipelines Thursday, March 19, 4:15PM – 5:15PM alongside Nina Arora-Rowland, Data and AI Practice Lead at Avanade/Accenture, and Colin Pop, Senior Director, Analytics Architect at Avanade. $TVGN $MSFT #AI #Biotech #FabCon #PrecisionMedicine #BigData #Analytics
Tevogen Bio tweet media
English
0
2
5
656
Tevogen Bio retweetledi
Mittul Mehta
Mittul Mehta@Head_TevogenAI·
Honored to see Tevogen.AI recognized by @Microsoft at #FabCon as an ISV. AI in biotech is shifting from models to systems—continuous learning, real-world feedback, and scale. Just getting started. #AI #Biotech $TVGN $MSFT @arunulag
Mittul Mehta tweet media
English
0
4
4
447
Tevogen Bio retweetledi
Ryan Saadi, Founder, TEVOGEN
Ryan Saadi, Founder, TEVOGEN@DrRyanSaadi·
🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive. $TVGN #NO #Dilution @dboralcapital
Tevogen Bio@TevogenBio

📰 globenewswire.com/news-release/2… 🔹Lead investor confirmed his intention to maintain his current shareholdings. 🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive. 🔹Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers. 🔹Company prioritizing long-term stock-based incentive program aligned with company milestones. 🔹Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders. 🔹Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue. 🔹Company exploring avenues to better reflect value of assets. $TVGN

English
1
2
5
1.1K
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… 🔹Lead investor confirmed his intention to maintain his current shareholdings. 🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive. 🔹Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers. 🔹Company prioritizing long-term stock-based incentive program aligned with company milestones. 🔹Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders. 🔹Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue. 🔹Company exploring avenues to better reflect value of assets. $TVGN
Tevogen Bio tweet media
English
0
2
5
1.2K
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… @Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can meaningfully increase success rates while lowering development risk. That combination has the potential to create significant long-term value.” @TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy
Tevogen Bio tweet media
English
0
3
5
290
Tevogen Bio
Tevogen Bio@TevogenBio·
📰 globenewswire.com/news-release/2… @DrRyanSaadi, Founder and CEO of Tevogen stated, "Long COVID is a clinical emergency affecting hundreds of millions of people globally. Our proof-of-concept data demonstrated that none of the patients treated with TVGN 489 for acute infection developed Long COVID. Our expanded HLA coverage now reaching 65% of the U.S. population, and potential digital health acquisitions move us toward building the infrastructure needed to launch our next clinical phase with precision and scale." $TVGN #LongCOVID #TCellTherapy #PublicHealth #LongCOVIDAwareness #LongCOVIDAwarenessMonth
Tevogen Bio tweet media
English
0
3
5
314

Keşfet

@DrRyanSaadi @JamesBarrood @TevogenAI @NJGov @Head_TevogenAI @NJBIZ @databricks @FABConSQLCon